Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12944195 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL29414597 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL29579452 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13110590 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL2734925 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL12094377 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13830646 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| Trifluoroacetic Acid SCHEMBL31096968 | 0.96 | PTPN1 (0.43) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL15088221 | 0.96 | HTR2A (0.40) | HTR2APTPN1SSTR3SIRT2SIRT1 | |
| SCHEMBL13311064 | 0.94 | FURIN (0.39) | HTR2APTPN1FURINSSTR3SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514926-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-12304925-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-05-01 | — | — | US | disclosed |
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12172986-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240360108-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3966229-A1 | GLYCOPEPTIDE VACCINE | Victoria Link Ltd (NZ) | 2022-03-16 | — | — | EP | disclosed |
| EP-3856258-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2021-08-04 | — | — | EP | disclosed |
| EP-3801632-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020252043-A1 | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020231274-A1 | GLYCOPEPTIDE VACCINE | VICTORIA LINK LTD (NZ) | 2020-11-19 | — | — | WO | disclosed |
| WO-2019232449-A9 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020065408-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2020-04-02 | — | — | WO | disclosed |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360108-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | HTR2A 3646/4885PTPN1 1896/4885FURIN 2401/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | HTR2A 3707/4885PTPN1 400/4885FURIN 2449/4885 |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | IL2, CD47, EPCAM | HTR2A 813/4885PTPN1 3213/4885FURIN 1312/4885 |
| US-12172986-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | HTR2A 3646/4885PTPN1 1896/4885FURIN 2401/4885 |
| US-20250135017-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, SNRPE, HNRNPAB | HTR2A 3925/4885PTPN1 2120/4885FURIN 3243/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | HTR2A 4369/4885PTPN1 851/4885FURIN 2314/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | HTR2A 3981/4885PTPN1 4059/4885FURIN 3060/4885 |
| US-12304925-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | HTR2A 4659/4885PTPN1 2620/4885FURIN 996/4885 |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | CD47, LNPEP, TIE1 | HTR2A 4199/4885PTPN1 1495/4885FURIN 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.